Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Recruiting · NCT06208007 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Medical Center Goettingen
View the official record on ClinicalTrials.gov →What this trial is about
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- ne or more of the following criteria:
- Age \> 60 years
- Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
- Diabetes mellitus Type I or II
- Atrial fibrillation
- Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
- BMI ≥ 30 kg/m2
- NYHA ≥ II
- E/e' \> 8
Exclusion criteria
- Left ventricular ejection fraction \< 50 %
- Significant valve disease (Grade III or higher)
- History of interventional or surgical valve repair
- Regional wall motion abnormalities
- Respiratory diseases as a known cause for dyspnea
- Atrial flutter or fibrillation during examination
- Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
- History of heart transplantation
Where it is running
1 location listed.
- Universitätsmedizin Göttingen - Göttingen, Lower Saxony, Germany